Short answer: it is not easy. Not yet. Retatrutide is still in clinical trials and has not received FDA approval or approval from most other regulatory bodies worldwide. You cannot walk into a pharmacy and pick it up. That is the reality right now.
But the full picture is more useful than just that. There are legitimate ways people are accessing it, and there are things you should know before you go looking.
Is Retatrutide Currently Available to the Public?
No. As of 2025, retatrutide is not approved for public use in the United States, Australia, the UK, or most other countries. Eli Lilly, the company developing it, is still running Phase 3 clinical trials.
Phase 3 is the last major testing stage before a drug goes to regulators for approval. Results from Phase 2 trials published in the New England Journal of Medicine in 2023 showed participants lost up to 24.2% of their body weight over 48 weeks. That number got a lot of attention. It is higher than what semaglutide and tirzepatide produce on average.
But strong trial results do not equal public availability. The FDA approval process after Phase 3 typically takes 12 to 24 months. Eli Lilly has not yet submitted a New Drug Application for retatrutide.
Can I Get Retatrutide Through a Prescription?
No doctor can legally prescribe retatrutide right now in most countries because it has no approved indication. There is no prescription pathway for an unapproved drug outside of a clinical trial or a specific compassionate use program.
In my experience, people searching for this are often hoping there is a grey area, a workaround, or a compounding pharmacy that can fill it. I will address those below. But the direct answer is: standard prescription access does not exist yet.
How Do I Qualify for a Retatrutide Clinical Trial?
This is the most legitimate way to access retatrutide right now. Eli Lilly is running multiple Phase 3 trials under the program name TRIUMPH.
To find trials you may qualify for:
- Go to ClinicalTrials.gov and search “retatrutide”
- Filter by status: “Recruiting”
- Filter by your country or region
- Read the inclusion and exclusion criteria carefully
- Contact the trial site directly to ask about eligibility screening
General eligibility criteria across most retatrutide trials include:
- BMI of 30 or higher, or BMI of 27 or higher with a weight-related condition like type 2 diabetes or high blood pressure
- No current use of other GLP-1 medications
- No history of certain thyroid cancers or pancreatitis
- Willingness to attend regular clinic visits
What I found when looking at active trials is that most sites are in the United States, Germany, Japan, and a handful of other countries. If you are in Australia or Southeast Asia, your options are more limited right now.
Participating in a trial means you may receive the drug or a placebo. You will not know which. That is the nature of a blinded trial. You also agree to close monitoring, which some people find valuable and others find inconvenient.
Is Retatrutide Available Online or Through Compounding Pharmacies?
This is where it gets complicated and where I want to be direct with you.
Some compounding pharmacies, particularly in the United States, have started offering what they call “retatrutide” as a compounded peptide. This happened with semaglutide and tirzepatide too, once those drugs became popular.
Here is the problem. Retatrutide is not on the FDA’s list of bulk drug substances that compounding pharmacies are permitted to use. That means any compounded version being sold right now exists in a legal grey area at best, and is outright illegal at worst depending on jurisdiction.
Beyond the legal issue, there is a quality issue. Compounded peptides are not subject to the same manufacturing standards as FDA-approved drugs. What I saw in reporting around compounded semaglutide was that some products contained incorrect dosages, contaminants, or were not the compound they claimed to be. The FDA issued multiple warnings about this.
Online sources selling retatrutide without a prescription, without a clinical trial, and without regulatory oversight are not a safe or reliable option. I would not recommend them.
What Is the Difference Between Retatrutide and Other Approved Weight Loss Drugs?
This matters because if you need access to a weight loss medication now, there are approved options that work well.
Here is how the main drugs compare:
Semaglutide (Ozempic, Wegovy)
Semaglutide targets one receptor, GLP-1. It produces average weight loss of around 15% of body weight over 68 weeks in trials. It is FDA-approved for weight management under the brand name Wegovy. It is available by prescription in many countries including the US, UK, and Australia.
Tirzepatide (Mounjaro, Zepbound)
Tirzepatide targets two receptors, GLP-1 and GIP. Average weight loss in trials was around 20-22% of body weight. It is FDA-approved for weight management under the brand name Zepbound. It is also available in many countries.
Retatrutide
Retatrutide targets three receptors, GLP-1, GIP, and glucagon. This triple agonist mechanism is what makes it different. In Phase 2 trials, average weight loss reached 17.5% at the highest dose over 24 weeks, with some participants reaching 24.2% at 48 weeks. Those numbers suggest it may outperform both semaglutide and tirzepatide, but head-to-head trials have not been completed.
The glucagon receptor activation is the key difference. Glucagon increases energy expenditure and fat breakdown. Adding that third mechanism appears to drive stronger fat loss, particularly visceral fat. A 2023 paper in the New England Journal of Medicine noted reductions in liver fat and improvements in metabolic markers beyond what dual agonists produce.
So how easy is it to get retatrutide compared to these approved drugs? Much harder. Semaglutide and tirzepatide are accessible through a doctor today. Retatrutide is not.
When Will Retatrutide Be Widely Available?
Based on Eli Lilly’s trial timeline and typical FDA review periods, the earliest realistic approval date is late 2026. Some analysts estimate 2027 is more likely given the complexity of Phase 3 data collection and regulatory review.
After approval in one country, other regulatory bodies like the TGA in Australia, the EMA in Europe, and Health Canada typically follow within 12 to 18 months. So international availability outside the US could stretch to 2028 in some regions.
That timeline can shift. If Phase 3 data is strong and Eli Lilly files quickly, approval could come sooner. If safety signals emerge, it could be delayed or require additional studies.
What Should You Do Right Now If You Want Retatrutide?
Here are the practical options in order of legitimacy and safety:
- Check ClinicalTrials.gov for recruiting trials. This is the only way to access retatrutide legally and safely right now. If you qualify and a site is near you, this is worth pursuing.
- Talk to a doctor about approved alternatives. Tirzepatide produces results close to what retatrutide has shown in early trials. It is available now. If weight loss is the goal, waiting two years for retatrutide while an effective approved drug exists is not a logical strategy.
- Avoid unregulated online sources. The risk is real. Contaminated or mislabeled compounds have caused harm. No weight loss outcome is worth that risk.
- Monitor Eli Lilly’s announcements. When Phase 3 results are published and a regulatory filing is made, that will be public news. That is the signal that approval is approaching.
FAQ
Can I buy retatrutide online right now?
You can find websites selling what they claim is retatrutide. These are not regulated, not verified, and not legal in most jurisdictions. The product may not be what it claims to be.
Is retatrutide the same as tirzepatide?
No. Tirzepatide is a dual agonist targeting GLP-1 and GIP. Retatrutide adds a third target, the glucagon receptor. They are different compounds with different mechanisms.
Does insurance cover retatrutide?
No. It is not approved, so no insurance plan covers it. Once approved, coverage will depend on your plan and country.
Is retatrutide safe?
Phase 2 trial data showed a side effect profile similar to other GLP-1 drugs, mainly nausea, vomiting, and diarrhea, most common during dose escalation. No major unexpected safety signals appeared in Phase 2. Phase 3 will provide more data on long-term safety.
Can a compounding pharmacy make retatrutide for me?
Not legally in the US or most other countries. Retatrutide is not on any approved compounding list. Any pharmacy offering it is operating outside regulatory guidelines.
What is the strongest weight loss drug available right now?
Based on current approved options, tirzepatide produces the highest average weight loss in clinical trials, around 20-22% of body weight. It is available by prescription in many countries.
The Bottom Line
Retatrutide shows real promise. The trial data is strong. But it is not available to the public and will not be for at least another one to two years in most countries. Working with a coach can provide personalized guidance on your weight management journey.
If you are serious about weight management now, approved GLP-1 medications work and are accessible through a doctor. If you want to be part of the retatrutide story before approval, a clinical trial is the right path. Everything else carries risk that is not worth taking.
